Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy: Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.

Comments

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News